1. Home
  2. CXAI vs PMCB Comparison

CXAI vs PMCB Comparison

Compare CXAI & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CXApp Inc.

CXAI

CXApp Inc.

N/A

Current Price

$0.25

Market Cap

9.5M

Sector

Technology

ML Signal

N/A

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

N/A

Current Price

$0.80

Market Cap

8.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CXAI
PMCB
Founded
N/A
1996
Country
United States
United States
Employees
41
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.5M
8.3M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
CXAI
PMCB
Price
$0.25
$0.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.6M
125.1K
Earning Date
03-20-2026
03-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
277.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$70.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.63
52 Week High
$1.49
$1.58

Technical Indicators

Market Signals
Indicator
CXAI
PMCB
Relative Strength Index (RSI) 53.64 57.19
Support Level $0.24 $0.65
Resistance Level $0.32 $1.05
Average True Range (ATR) 0.04 0.07
MACD 0.01 0.01
Stochastic Oscillator 55.81 84.79

Price Performance

Historical Comparison
CXAI
PMCB

About CXAI CXApp Inc.

CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: